GERON CORP
GERN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GERN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GERN
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing its telomerase inhibitor, RYTELO (imetelstat), for myeloid hematologic malignancies, with an approved indication in lower-risk MDS and ongoing clinical trials in myelofibrosis and other indications.
Key risk: Commercialization risk for RYTELO
BioSniper Score
Based on 5 of 6 signals
Market Cap
$970.1M
Cash Runway
36.2 moLead Asset
imetelstat (Phase 3)Next Catalyst
Phase3_Topline · Oct 13, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 3 catalysts · 1 FDA decision for GERON CORP.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing its telomerase inhibitor, RYTELO (imetelstat), for myeloid hematologic malignancies, with an approved indication in lower-risk MDS and ongoing clinical trials in myelofibrosis and other indications.
- Geron's sole approved product is RYTELO (imetelstat), a telomerase inhibitor for lower-risk MDS, with commercialization efforts underway in the U.S. and a recent marketing authorization in the EU [sec_mda · as of 2025-11-07].
- As of 2026-06-30, the company reported cash & equivalents of $64.5M, total revenue of $57.5M, net income of -$16.7M, shareholders' equity of $259.5M, and total debt of $120.1M [sec].
- Geron is conducting multiple clinical trials for RYTELO, including the IMpactMF Phase 3 trial in myelofibrosis, a Phase 1 IMproveMF combination trial in frontline MF, and a Phase 2 investigator-led IMpress trial in higher-risk MDS and acute myeloid leukemia [sec_mda · as of 2025-11-07].
- The company has not yet achieved meaningful sales growth from RYTELO and may need to adjust its commercialization strategy; no sales of common stock have occurred under the 2026 Sales Agreement as of 2026-08-05 [sec_mda · as of 2026-08-05].
What works
- RYTELO has received marketing authorization in the EU, expanding its potential market beyond the U.S. [sec_mda · as of 2025-11-07].
- The company is advancing a broad clinical development program for RYTELO across multiple myeloid malignancies, including myelofibrosis and higher-risk MDS, which could expand its label and revenue base [sec_mda · as of 2025-11-07].
- Geron maintains a conservative investment policy with no exposure to sub-prime mortgages or asset-backed securities, and has not experienced lack of access to its cash [sec_mda · as of 2026-08-05].
What to weigh
- Geron's commercialization strategy for RYTELO has not yet achieved meaningful sales growth, and there is no assurance that future sales will increase [sec_mda · as of 2026-08-05].
- The company expects research and development expenses and selling, general and administrative expenses to increase as it continues to support commercialization and clinical trials, which may require additional funding [sec_mda · as of 2025-11-07].
- Future capital requirements are difficult to forecast and depend on factors such as market acceptance of RYTELO and the costs of clinical development, and adequate funding may not be available when needed [sec_mda · as of 2025-11-07].
From the filings
Quoted directly from source documents.
Commercial execution strategy has not yet achieved meaningful sales growth.
“our strategy to drive sales growth and our ongoing commercialization efforts have not to date achieved and may not in the future achieve meaningful sales growth”
SEC MD&A · August 5, 2026
RYTELO has received marketing authorization in the EU.
“recent marketing authorization in the EU”
SEC MD&A · November 7, 2025
No sales of common stock have occurred under the 2026 Sales Agreement.
“To date, no sales of common stock have occurred under the 2026 Sales Agreement.”
SEC MD&A · August 5, 2026
Geron is developing RYTELO for multiple myeloid hematologic malignancies.
“developing RYTELO for the treatment of several myeloid hematologic malignancies that will continue to require additional time and significant investment in clinical trials to complete”
SEC MD&A · August 6, 2025
Catalyst timeline
- 2026-10-13 · Phase3_Topline · ipss — Phase 3 Topline: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermed — Topline results from this Phase 3 trial in lower-risk MDS will inform potential label expansion or confirmatory data.
- 2028-06-30 · Phase3_Topline · intermediate-2 — Phase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap — Topline results from this Phase 3 trial in intermediate-2 risk MDS or myelofibrosis will be a key efficacy readout.
- 2039-06-16 · Patent_Expiry · RYTELO — Patent/Exclusivity Expiry: RYTELO — Patent expiry for RYTELO could open the door to generic competition, affecting long-term revenue.
Risks & what to watch (3)›
Key risks
- Commercialization risk for RYTELO — Sales growth may not materialize, requiring strategy adjustments and additional expenses [sec_mda · as of 2026-08-05].
- Capital needs and funding uncertainty — Future capital requirements are difficult to forecast; adequate funding may not be available [sec_mda · as of 2025-11-07].
- Clinical trial and regulatory delays — Development of RYTELO for additional indications requires significant time and investment, with no guarantee of success [sec_mda · as of 2025-08-06].
What to watch
- Topline data from the Phase 3 IMpactMF trial in myelofibrosis, expected by 2028-06-30 [catalyst].
- Topline data from the Phase 3 trial in IPSS low or intermediate-1 risk MDS, expected by 2026-10-13 [catalyst].
- Commercial sales trajectory of RYTELO in the U.S. and EU, and any updates on commercialization strategy [sec_mda · as of 2026-08-05].
- Patent/exclusivity expiry for RYTELO on 2039-06-16, which could affect long-term market exclusivity [catalyst].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run GERON CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GERON CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
36.2 months
D/E 1.37
Lead: Approved
2 candidates
3 upcoming, next in ~44d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
252
Total value held
$676.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 63,771,366 | $95.0M |
| vanguard capital management llc | 53,338,058 | $79.5M |
| blackrock, inc. | 47,319,779 | $70.5M |
| deep track capital, lp | 31,720,278 | $47.3M |
| state street corp | 30,497,183 | $45.4M |
| citadel advisors llc | 22,110,669 | $32.9M |
| clearbridge investments, llc | 19,620,320 | $29.2M |
| vivo capital, llc | 17,343,594 | $25.8M |
| geode capital management, llc | 13,670,785 | $20.4M |
| morgan stanley | 12,665,119 | $18.9M |
Showing top 10 of 252 institutional holders of GERON CORP. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 11.8%
- Days to cover
- 4.2
- Shares short
- 75,696,666
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GERN short interestGovernance
Frequently asked questions
What is the AI investment thesis for GERON CORP?
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing its telomerase inhibitor, RYTELO (imetelstat), for myeloid hematologic malignancies, with an approved indication in lower-risk MDS and ongoing clinical trials in myelofibrosis and other indications.
What is GERON CORP's lead drug candidate?
GERON CORP's most advanced tracked candidate is imetelstat (Phase 3) for Myelofibrosis; Multiple Myeloma; Myelodysplastic Syndromes.
What is GERON CORP's next catalyst?
GERON CORP's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermed" — expected October 13, 2026.
Who is the CEO of GERON CORP?
Mr. Harout Semerjian is the chief executive officer of GERON CORP (GERN).
Where is GERON CORP headquartered?
GERON CORP (GERN) is headquartered in Foster City, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.